Research report, page-16

RNA based drugs have come of age. Extraordinary insights that come from an intimate knowledge of drug development and how Pharma is slow to catch on at first then scared of missing the boat once hurdles are overcome and therapies start becoming available.

The article also highlights the importance of CD49d as a target in inflammation. Once the causal relationship between the target and disease indication is established then it becomes a matter of looking for diseases where CD49d plays an important role. If I remember correctly, corticosteroids are used in up to 100 different disease indications where inflammation is chronic.

Will it be a case of pharma FOMO? One takeaway from recent developments is that after 20 years in the backwaters, ANP finds itself in the box seat.